Trial Profile
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Bevacizumab; Cetuximab; Fluorouracil; Folinic acid; Irinotecan; Levofolinic acid; Oxaliplatin
- Indications Carcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-177; KN177
- Sponsors Merck Sharp & Dohme Corp.
- 24 Oct 2023 Results (at data cutoff date: 17 Jul 2023) reporting efficacy and safety data at 5 years of follow-up presented at the 48th European Society for Medical Oncology Congress
- 13 Sep 2023 This trial has been completed in Germany, according to the European Clinical Trials Database record.
- 27 Jul 2023 This trial has been completed in Belgium (Date of the global end of the trial: 17-Jul-2023), according to the European Clinical Trials Database record.